SCHEMBL13445696

SCHEMBL13445696

O=C(Cl)c1cc(Br)c(F)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
ALOX15 P16050 1/20 0.41
PLAU P00749 1/20 0.41
ELANE P08246 1/20 0.41
KDM1A O60341 2/20 0.40
KDM1B Q8NB78 2/20 0.40
POLB P06746 1/20 0.40
APEX1 P27695 1/20 0.40
HPGD P15428 5/20 0.39
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
TSHR P16473 2/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 4/20 0.36
GAA P10253 1/20 0.34
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366229 0.92 KDM1A (0.43) ALDH1A1ALOX15PLAUELANEKDM1A
SCHEMBL3336346 0.84 ALDH1A1 (0.41) ALDH1A1ALOX15PLAUELANEKDM1A
SCHEMBL30577298 0.84 CA12 (0.46) ALDH1A1PLAUELANEPOLBAPEX1
SCHEMBL1552250 0.84 CA12 (0.46) ALDH1A1PLAUELANEPOLBAPEX1
SCHEMBL13250855 0.83 ALDH1A1 (0.43) ALDH1A1ALOX15KDM1AKDM1BHPGD
SCHEMBL3820327 0.83 POLB (0.53) ALDH1A1ALOX15PLAUELANEPOLB
SCHEMBL7929417 0.81 ALDH1A1 (0.45) ALDH1A1ALOX15PLAUELANEKDM1A
SCHEMBL591163 0.79 ALDH1A1 (0.43) ALDH1A1ALOX15PLAUELANEKDM1A
SCHEMBL18981860 0.78 GAA (0.49) ALDH1A1POLBAPEX1HPGDNPC1
SCHEMBL13538980 0.78 POLB (0.50) POLBAPEX1HPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9061060-B2 Deuterated benzylbenzene derivatives and methods of use THERACOS INC. (US) 2015-06-23 US disclosed
US-9061060-B2 Deuterated benzylbenzene derivatives and methods of use THERACOS INC. (US) 2015-06-23 US disclosed
US-20100063141-A1 DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE THERACOS, INC. (US) 2010-03-11 US disclosed
US-20100063141-A1 DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE THERACOS, INC. (US) 2010-03-11 US disclosed
WO-2010009243-A1 DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE THERACOS, INC. (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063141-A1 DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE SLC5A1, SLC5A2, SLC2A4 ALDH1A1 1191/4885ALOX15 2268/4885PLAU 3619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.